Clara Raquel Epstein, MD
is One of the First Surgeons to Become Certified in
an Innovative FDA Approved Minimally Invasive Spine Procedure
The
TranS1® AxiaLIF® 2L Technique for
minimally invasive Spine Surgery was
recently FDA approved. Dr. Epstein is
one of the first ten spine surgeons to
become certified in the US in this novel
two level spine technique at the most
recent course held in Denver, Colorado.
This course was presented by Josue P.
Gabriel, MD, an Orthopaedic Surgeon who
subspecializes in Spine Surgery. He is
one of the pioneering experts in the
application of this innovative
technology.
AxiaLIF®
2L Training took place on Saturday,
November 15, 2008 in Denver, Colorado at
The University of Colorado, Denver
Health Sciences Center, Research Complex
1 North,
12800 East 19th Ave, Aurora, Colorado
80045.
TranS1®
pioneered an innovative, trans-sacral
approach to lumbar surgery. A
percutaneous access and fusion system
enables lumbar fusion to be performed
with complete preservation of the
annulus and all paraspinal soft tissue
structures. The AxiaLIF® (Axial Lumbar
Interbody Fusion) System includes
surgical instruments for creating a safe
and reproducible pre-sacral access route
to the L4 - L5 - S1 vertebral bodies.
The AxiaLIF® technique features novel
instrumentation to enable standard of
care fusion principles, distraction and
stabilization of the anterior lumbar
column while mitigating the soft tissue
trauma associated with traditional
lumbar fusion through open surgical
incisions.
Using
AxiaLIF®, the lumbar spine is accessed
through a percutaneous opening adjacent
to the sacral bone. This atraumatic
tissue plane alleviates the need for the
surgeon to cut through soft tissues like
muscles and ligaments, thus lessening
patient pain and the likelihood of
complications.*
TranS1®
AxiaLIF® System is intended to provide
anterior stabilization of the L4-L5,
L5-S1 spinal segments as an adjunct to
spinal fusion.
Indications:
-
Degenerative Disc Disease (DDD) with
or without radicular symptoms
-
Pseudoarthrosis (unsuccessful
previous fusion)
-
Spondylolisthesis (Grade 1 or 2)
* as
presented at IMAST BANFF, July 2005.
TranS1®, Inc. is
a publicly held
medical device
company traded
on NASDAQ as
TSON focused on
developing
innovative,
minimally
invasive
surgical
procedures for
treatment of low
back pain (LBP).
Content provided
by:
TranS1® AxiaLIF®
2L
